Ferdinandos Skoulidis, M.D., Ph.D., MRCP
Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor (Term Tenure), Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Member of Graduate Faculty, Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, TX
Education & Training
Degree-Granting Education
| 2011 | University of Cambridge, Cambridge, GB, Oncology, Ph.D |
| 2000 | Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, GR, Medicine, MD (Ptychio Iatrikes) |
Postgraduate Training
| 2013-2014 | Rotating Fellow, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2010-2013 | Academic Clinical Lecturer in Medical Oncology and Honorary Specialist Registrar (Clinical Fellowship combined with post-doctoral training), Medical Oncology, University of Cambridge, Cambridge |
| 2005-2006 | Specialist Registrar in Medical Oncology (Clinical Fellowship), Medical Oncology, St. Bartholomew's Hospital, London |
| 2005-2005 | Research Fellow, GI Oncology/Lymphoma, Royal Marsden Hospital, Sutton |
| 2004-2005 | Senior House Officer in Oncology, Oncology, Royal Marsden Hospital, Sutton |
| 2002-2004 | Senior House Officer (Clinical Residency), Addenbrooke's SHO General Medical Rotation, Addenbrooke's Hospital, Cambridge |
| 2001-2002 | Pre-registration House Officer, Medicine, Royal Devon and Exeter Hospital, Exeter |
Licenses & Certifications
| 2021 | Medical Oncology |
| 2019 | Internal Medicine |
| 2018 | Physician License |
| 2017 | Faculty Temporary License |
| 2016 | Faculty Temporary License |
| 2015 | Faculty Temporary License |
| 2013 | General Medical Council Specialist Register, Medical Oncology (analogous to Board Certification in Medical Oncology) |
| 2004 | Membership of the Royal College of Physician of the United Kingdom (analogous to Board Certification in Internal Medicine) |
Experience & Service
Faculty Academic Appointments
Assistant Professor (Tenure-Track), Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2021
Instructor (Advanced Scholar), Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2015
Academic Clinical Lecturer, Department of Oncology, University of Cambridge, Cambridge, 2010 - 2013
Administrative Appointments/Responsibilities
Deputy Director of Translational Research, The University of Texas MD Anderson Cancer Center, 2024 - Present
Co-Chair, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member of Governing Body, Clare Hall College, University of Cambridge, Cambridge, 2012 - 2013
Other Professional Positions
Member, Revolution Medicines Global Lung Cancer Advisory Council, 2025 - Present
US Lead PI and Member, Krascendo-2 randomized phase III clinical trial Steering Committee, 2025 - Present
Member, Divarasib Global Strategic Council, 2024 - Present
Member, CodeBreaK 202 randomized phase III clinical trial Steering Committee, 2024 - Present
Chair, Krascendo-1 randomized phase III clinical trial Steering Committee, 2024 - Present
Member, TRITON randomized phase III clinical trial Steering Committee, 2023 - Present
Member, Basic and Translational Science Committee, International Association for the Study of Lung Cancer, 2023 - 2027
Research Fellow in the Sciences and Voting Member of Clare Hall College Governing Body, Clare Hall College, Cambridge, 2012 - 2013
Clinical Supervisor, Murray Edwards College, University of Cambridge, School of Clinical Medicine, Cambridge, 2002 - 2004
Honors & Awards
| 2024 | Hope Award - KRAS Team, Rexanna’s Foundation for Fighting Lung Cancer |
| 2020 | Tami Hissom Research, Rexanna’s Foundation for Fighting Lung Cancer |
| 2020 | FY 2020 Perfect Score Provider (ranked in 1% of providers nationally by patients), CGCAHPS |
| 2019 | Hope Award, Rexanna’s Foundation for Fighting Lung Cancer |
| 2019 | AACR NextGen Stars Award, American Association for Cancer Research |
| 2018 - Present | T.J. Martell Foundation Award, The University of Texas MD Anderson Cancer Center |
| 2018 | Best Poster Award, WIN Symposium 2018 |
| 2017 | Waun Ki Hong Award for Excellence in Team Science, Division of Cancer Medicine, MD Anderson Cancer Center |
| 2016 - 2024 | Andrew Sabin Family Foundation Fellowship, UT MD Anderson Cancer Center |
| 2016 - 2024 | Lung Cancer Research Program Career Development Award, Department of Defence |
| 2016 - 2024 | UT Rising Stars Award, University of Texas System |
| 2015 | University of Texas Lung SPORE Career Development Award, University of Texas Lung SPORE |
| 2015 - 2024 | Khalifa Scholar Award, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, UT MD Anderson Cancer Center |
| 2015 - 2024 | Physician Scientist Program, UT MD Anderson Cancer Center |
| 2014 | AACR Scholar-in-Training Award, AACR |
| 2013 | MRC-CCU Centenary Award, Medical Research Council Cancer Cell Unit |
| 2012 - 2013 | Research Fellowship in the Sciences, Clare Hall College, University of Cambridge |
| 2012 | 2011 Cancer Research-UK Pontecorvo Prize finalist (top 5), Cancer Research-UK |
| 2011 | European Society of Surgical Oncology Fellowship Travel Grant, European Society of Surgical Oncology (ESSO) |
| 2011 | Research Paper of the Year, East of England Multi-Professional Deanery |
| 2011 | Winner, Medical Research Society Young Investigator Competition, Academy of Medical Sciences/Medical Research Society/ Royal College of Physicians |
| 2006 - 2024 | Marquis Who’s Who Listee, Marquis Who is Who |
| 2006 - 2009 | Cancer Research UK Clinical Research Training Fellowship, Cancer Research-UK |
| 2006 | Medical Research Council Studentship, Medical Reseach Council |
| 2003 | Postgraduate Fellowship, Onassis Foundation |
| 2000 | Orator of the Hippocratic Oath, Aristotle University of Thessaloniki, School of Medicine |
| 2000 | Socrates/Erasmus Scholarship, Aristotle University of Thessaloniki |
| 1999 | Winner of 3rd Prize, 3rd Olympiad of Medical Knowledge, Scientific Association of Greek Medical Students |
| 1994 - 2000 | Undergraduate Scholarship, Bodossaki Foundation |
| 1994 | Prize, Bodossaki Foundation |
| 1994 | Prize, IKY (Greek National Scholarship Foundation) |
| 1994 | Prize, Lilian Boudouri Foundation |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2014. De-constructing KRAS-mutant lung adenocarcinoma. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2013. Discovery signatures : KL/KP. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2013. De-constructing lung adenocarcinoma driven by oncogenic KRAS. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2013. Impact of co-occurring genetic events on the signaling landscape of KRAS-mutant lung adenocarcinoma. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
National Presentations
- 2019. Oral Session: Systematic Eludicdation of nononcongene targets. Invited. AACR Annual Meeting 2019. Atlanta, GA, US.
- 2017. Oral Presentation: LKB1 inactivation predicts for de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant LUAC. Conference. Lung Spore Workshop 2017. New Haven, CT, US.
- 2016. Poster presentation : " Impact of APOBEC mutagenesis on the immune micro-environment of lung adenocarcinoma (LUAC)". Conference. AACR Annual Meeting 2016. New Orleans, LA, US.
- 2016. Poster presentation : "Loss of LKB1 mediates an immune inert phenotype in human lung adenocarcinoma". Conference. AACR Annual Meeting 2016. New Orleans, LA, US.
- 2015. Oral presentation : "Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles and therapeutic vulnerabilities". Conference. Lung Cancer SPORE Workshop. Rockville, MD, US.
- 2015. Poster presentation : "Impact of co-occurring genetic events on RAS signalling diversification in NF1-mutant lung adenocarcinoma (LUAC)". Conference. AACR Annual Meeting 2015. Philadelphia, PA, US.
- 2015. Oral presentation : "Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology and therapeutic vulnerabilities". Conference. AACR Annual Meeting 2015. Philadephia, PA, US.
- 2015. Oral Presentation : "P53 regulation of PDL1 is mediated through miR-34a". Conference. AACR Annual Meeting 2015. Philadelphia, PA, US.
- 2014. Poster Presentaton : "Systematic analysis of co-mutations unveils biologically relevant subsets of KRAS-driven lung adenocarcinoma with distinct therapeutic vulnerabilities". Conference. AACR Special Conference on RAS Oncogenes: From Biology to Therapy. Lake Buena Vista, FL, US.
- 2014. Poster presentation : "Co-mutations define major subsets of KRAS-driven lung adenocarcinoma with implications for targeted therapy". Conference. AACR Annual Meeting 2014. San Diego, CA, US.
- 2011. Oral presentation : "Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer". Conference. Gordon Research Conference on Cancer Genetics and Epigenetics. Ventura, CA, US.
International Presentations
- 2019. Oral Session: Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. Conference. ASCO Annual Meeting 2019. Chicago, US.
- 2019. Poster Presentation: Randomized phase I/II trial of pembrolizumab with and without radiotherapy for metastatic non-small cell lung cancer. Conference. ASCO Annual Meeting 2019. Chicago, US.
- 2018. Presention-Impact of STK11/LKB1 Genomic Alterations on Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC. Conference. IASC World Conference Lung Cancer 2018. Toronto, US.
- 2018. Poster Presentation: Association of STK11/LKB1 mutations with primary resistnace to PD-1/PD-L1 axis blackade in PD-L1 positive non-sqaumous NSCLC. Conference. ASCO Annual Meeting 2018. Chicago, US.
- 2018. Poster Presentation: LKB1 and KEAP1/NRF2 PATHWAYS COPERATIVELY PROMOTE GLUTAMINE DEPENDANCE AND VULNERABILITY TO GLUTAMIASE INHIBOTRS IN KRAS-mutatn lung adenocarcinoma. Conference. AACR Annual Meeting 2018. Atlanta, US.
- 2017. Molecular determinants of response to PD-1 axis blockade in non-small cell lung cancer. Invited. Emirates Oncology Conference 2017. Abu Dhabi, AE.
- 2017. STK11/LKB1 Loss of Function Genomic Alterations Predict Primary Resistance to PD-1/PD-L1 AXIS Blockade in KRAS-Mutant NSCL. Conference. IASLC 18th World Conference on Lung Cancer (IASLC WCLC 2017). Pacifico Yokohama, JP.
- 2017. STK11/LKB1 co-mutations predict for de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma. Conference. ASCO Annual Conference 2017. Chicago, US.
- 2016. Impact of major co-mutations on the immune contexture and response of KRAS-mutant lung adenocarcinoma to immunotherapy. Conference. IASLC 17th World Lung Cancer Conference, AT.
- 2016. Oral presentation: "Impact of co-mutations on the immune micro-environment of KRAS-mutant lung adenocarcinoma". Invited. 4th AACR-IASLC International Joint Conference Lung Cancer Translational Science From the Bench to the Clinic. San Diego, US.
- 2015. Oral presentation : "Landscape and Functional Significance of KRAS Co-mutations in Lung Adenocarcinoma (LUAC)". Conference. 16th World Conference on Lung Cancer. Denver, US.
- 2015. Oral presentation : "Inactivation of STK11/LKB1 is associated with a suppressive immune micro-environment in lung adenocarcinoma (LUAC)". Conference. ASCO Annual Meeting 2015. Chicago, US.
- 2013. Mini-oral presentation : "Impact of co-occurring genetic mutations on the signaling landscape of KRAS-mutant lung adenocarcinoma". Conference. IASCL 15th World Lung Cancer Conference. Sydney, AU.
- 2012. Poster presentation : "An integrated cross-species approach for the discovery of serum-based diagnostic biomarkers of PDAC using genetically engineered murine models (GEMMs)". Conference. ASCO 2012 Gastrointestinal Cancers Symposium. San Fransisco, US.
- 2011. Oral presentation : "Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer". Conference. Zing Cancer Conference “From carcinogenesis to cancer therapy”. Xcaret, MX.
- 2011. Poster presentation : "Ipilimumab immunotherapy in the treatment of metastatic melanoma : A single institution experience". Conference. National Cancer Research Institute Annual Meeting. Liverpool, GB.
- 2011. Oral presentation : "Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer". Conference. Medical Research Society/Academy of Medican Sciences/Royal College of Physicians Clinician Scientists in Training Meeting. London, GB.
- 2010. Oral presentation : "Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer". Conference. Iddibell Cancer Conference on Mouse Models of Cancer. Barcelona, ES.
- 2009. Oral presentation: "BRCA2 in pancreatic carcinogenesis: when you don’t need to go all the way". Conference. Cancer Research UK Cambridge Research Institute "Models and mechanisms of cancer” mini-symposium. Cambridge, GB.
Formal Peers
- 2015. "Deconstructing KRAS-mutant lung adenocarcinoma". Invited. Baku, AZ.
- 2012. "BRCA2 in pancreatic carcinogenesis : novel insights and clinical translation". Invited. Cambridge, GB.
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | Elucidating roles of the CD24 ligand in early lung cancer development, immune evasion and response to KRAS targeted therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 1 R01CA301423-01 |
| Date: | 2023 - 2028 |
| Title: | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 5R01CA279452-02 |
| Date: | 2023 - 2028 |
| Title: | Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5R01 CA279194-03 |
| Date: | 2022 - 2025 |
| Title: | Evaluating the antitumor efficacy of RAS(ON) inhibitors in immune-competent models of KRAS-mutant NSCLC, Sponsored Research Agreement |
| Funding Source: | Revolutions Medicine |
| Role: | PI |
| Date: | 2021 - 2026 |
| Title: | Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5R01 CA262469-04 |
| Date: | 2021 - 2026 |
| Title: | Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer |
| Funding Source: | NIH |
| Role: | PI |
| ID: | 13216707 |
| Date: | 2021 - 2023 |
| Title: | Overcoming lung cancer immunotherapy resistance by targeting Bone Morphogenetic Proteins |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | W81XWH-21-1-0336 |
| Date: | 2020 - 2025 |
| Title: | Project 2: Targeting Immune Vulnerabilities in Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | P50-CA70907-21 |
| Date: | 2020 - Present |
| Title: | Tammy Hissom Research Grant |
| Funding Source: | Rexanna’s Foundation for Fighting Lung Cancer |
| Role: | PI |
| Date: | 2020 - 2023 |
| Title: | Elucidating Aberrant Splicing-Induced Immune Pathway Activation in RBM10-Deficient KRAS-Mutant NSCLC and Harnessing Its Potential for Precision Immunotherapy |
| Funding Source: | Cancer Prevention and Research Institute of Texas Individual Investigator Research |
| Role: | PI |
| ID: | RP200287 |
| Date: | 2019 - 2014 |
| Title: | Project 1: Targeting Metabolic Vulnerabilities in Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | P50-CA070907-21 |
| Date: | 2019 - 2020 |
| Title: | Project 1: Molecular Signatures for Individualizing Lung Cancer Therapy |
| Funding Source: | NIH/NCI Bridge Funding |
| Role: | Co-PI |
| ID: | 5P50CA70907 |
| Date: | 2019 - 2022 |
| Title: | Expanding Therapeutic Options for Lung Cancer (EXTOL) in memory of Waun Ki Hong |
| Funding Source: | Memorial Sloan Kettering Cancer Center/The Mark Foundation |
| Role: | Co-PI |
| ID: | 19-028-ASP |
| Date: | 2018 - 2019 |
| Title: | Mechanisms of carcinogenesis associated with RBM10 inactivation in KRAS-mutant lung adenocarcinoma, T.J. Martell Foundation Award |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2017 - 2019 |
| Title: | “Modeling the impact of APOBEC mutagenesis on the immune contexture and immunotherapy response of non‐small cell lung cancer (NSCLC)” |
| Funding Source: | MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2016 - 2021 |
| Title: | Defining and Defeating Mechanistic Subtypes of KRAS-mutant Lung Cancers Cancer Prevention & Research Institute of Texas |
| Funding Source: | CPRIT |
| Role: | Co-PI |
| ID: | RP160652 |
| Date: | 2016 - 2019 |
| Title: | Mechanisms of carcinogenesis and therapeutic vulnerabilities associated with RBM10 loss in KRAS- mutant NSCLC |
| Funding Source: | DOD |
| Role: | PI |
| Date: | 2016 - 2019 |
| Title: | Impact of NLRC5 loss on the biology, immune contexture and response of KRAS-mutant lung adenocarcinoma (LUAC) to immunotherapy |
| Funding Source: | Andrew Sabin Family Foundation Fellowship |
| Role: | PI |
| Date: | 2015 - 2018 |
| Title: | Elucidating mechanisms of carcinogenesis and therapeutic vulnerabilities associated with RBM10 inactivation in lung adencarcinoma |
| Funding Source: | Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy |
| Role: | PI |
| Date: | 2015 - 2021 |
| Title: | AACR Stand Up to Cancer American Cancer Society Lung Cancer Translational Research Dream Team |
| Funding Source: | AACR |
| Role: | Co-PI |
| ID: | SU2C-AACR-DT17-15 |
| Date: | 2015 - 2015 |
| Title: | Dissecting the tumor suppressive role of RBM10 in lung carcinogenesis |
| Funding Source: | University of Texas Lung Cancer SPORE Career Development Award |
| Role: | PI |
| Date: | 2014 - 2016 |
| Title: | Impact of NF1 inactivation on the pathogenesis, signaling circuitry and therapeutic responsiveness of NSCLC in a novel co-clinical trial of targeted therapy |
| Funding Source: | United Against Lung Cancer Legacy Program |
| Role: | PI |
| Date: | 2012 - 2014 |
| Title: | Genetic and molecular evolution of pancreatic cancer in carriers of pathogenic mutations in the BRCA2 breast cancer susceptibility gene |
| Funding Source: | Academy of Medical Sciences (UK) |
| Role: | PI |
| Title: | Elucidating roles of the CD24 ligand in early lung cancer development, immune evasion and response to KRAS targeted therapy |
| Funding Source: | CPRIT |
| Role: | Co-PI |
| Title: | Therapeutic approaches for LKB1-deficient non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R01 CA205150-01 |
| Title: | A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer (IM-BATTLE-2-Program) (Investigator-Sponsored Study) |
| Funding Source: | MDACC/NCI/Merck&Co/Novartis |
| Role: | PI |
| ID: | 2017-0226 |
Selected Publications
Peer-Reviewed Articles
- Skoulidis F, Li BT, de Langen AJ, Hong DS, Lena H, Wolf J, Dy GK, Curioni Fontecedro A, Tomasini P, Velcheti V, van der Wekken AJ, Dooms C, Paz-Ares Rodriguez L, Mountzios G, Sacher A, Nadal E, Couraud S, Kim SW, O'Byrne K, Rocco D, Toyozawa R, Chmielewska I, Lindsay CR, Hindoyan A, Mukundan L, Wilmanski T, Anderson A, Ardito-Abraham C, Pati A, Reddy A, Mehta B, Schuler M. Molecular determinants of sotorasib clinical efficacy in KRAS(G12C)-mutated non-small-cell lung cancer. Nat Med 31(8):2755-2767, 2025. e-Pub 2025. PMID: 40437272.
- Di Federico A, Stumpo S, Mantuano F, De Giglio A, Lo Bianco F, Pecci F, Alessi J, Wang X, Sperandi F, Melotti B, Gelsomino F, Skoulidis F, Garassino M, Peters S, Awad MM, Ardizzoni A, Ricciuti B. Long-term overall survival with dual CTLA-4 and PD-(L)1 blockade in patients with advanced non-small cell lung cancer and outcomes by PD-L1 expression, histology, and KRAS and STK11 mutational status: a systematic review and reconstructed individual patient data meta-analysis. Lancet Oncol. e-Pub 2025.
- Xia, Y, Wang, K, Zhao, J, Arter, Z, Zhang, Y, Zhou, J, Lu, Y, Zeng, L, Du, R, Owens, J, Elamin, YY, Gay, CM, Skoulidis, F, Tsao, A, Lu, C, Cascone, T, Gibbons, DL, Zhang, J, Chen, O, Mok, K, Nagasaka, M, Li, W, Heymach, JV, Ignatius Ou, SH, Li, M, Le, X. Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC. Journal of Thoracic Oncology 20(4):465-474, 2025. e-Pub 2025. PMID: 39622411.
- Vailati Negrao, M, Paula, AG, Molkentine, D, Hover, LD, Nilsson, M, Vokes, N, Engstrom, LD, Calinisan, A, Briere, DM, Waters, L, Hallin, J, Diao, L, Altan, M, Blumenschein, GR, Skoulidis, F, Wang, J, Kopetz, S, Hong, DS, Gibbons, DL, Olson, P, Christensen, JG, Heymach, JV. Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. Clinical Cancer Research 31(6):1069-1081, 2025. e-Pub 2025. PMID: 39804166.
- De Langen, AJ, Johnson, M, Mazieres, J, Dingemans, AM, Mountzios, G, Pless, M, Wolf, J, Schuler, M, Lena, H, Skoulidis, F, Yoneshima, Y, Kim, SW, Linardou, H, Novello, S, van der Wekken, AJ, Chen, Y, Peters, S, Felip, E, Solomon, BJ, Ramalingam, SS, Dooms, C, Lindsay, CR, Ferreira, CG, Blais, N, Obiozor, C, Wang, Y, Mehta, B, Varrieur, T, Ngarmchamnanrith, G, Stollenwerk, B, Waterhouse, DM, Paz-Ares, L. Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer. Future Oncology 21(9):1033-1044, 2025. e-Pub 2025. PMID: 40129223.
- Skoulidis, F, Li, BT, Hochmair, M, Govindan, R, Vincent, M, van der Wekken, AJ, Aransay, NR, O'Byrne, KJ, Girard, N, Griesinger, F, Nishio, M, Häfliger, S, Lindsay, CR, Reinmuth, N, Paulus, A, Papakotoulas, P, Kim, SW, Ferreira, CG, Pasello, G, Duruisseaux, M, Gennatas, S, Dimou, A, Mehta, B, Kormany, W, Nduka, C, Sylvester, B, Ardito-Abraham, CM, Wang, Y, De Langen, AJ. Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer. Oncologist 30(1), 2025. e-Pub 2025. PMID: 39846981.
- Skoulidis, F, Araujo, HA, Do, MT, Qian, Y, Sun, X, Cobo, AG, Le, JT, Montesion, M, Palmer, R, Jahchan, NS, Juan, J, Min, C, Yu, Y, Pan, X, Arbour, KC, Vokes, N, Schmidt, S, Molkentine, D, Owen, D, Memmott, R, Patil, P, Marmarelis, ME, Awad, MM, Murray, J, Hellyer, JA, Gainor, J, Dimou, A, Bestvina, CM, Shu, CA, Riess, JW, Blakely, CM, Pecot, CV, Mezquita, L, Tabbò, F, Scheffler, M, Digumarthy, S, Mooradian, MJ, Sacher, A, Lau, SC, Saltos, A, Rotow, JK, Johnson, RP, Liu, C, Stewart, TF, Goldberg, SB, Killam, J, Walther, Z, Schalper, K, Davies, KD, Woodcock, MG, Anagnostou, V, Marrone, KA, Forde, PM, Ricciuti, B, Venkatraman, D, Van Allen, EM, Cummings, AL, Goldman, JW, Shaish, H, Kier, M, Katz, S, Aggarwal, C, Ni, Y, Azok, J, Segal, J, Ritterhouse, LL, Neal, JW, Lacroix, L, Elamin, YY, Vailati Negrao, M, Le, X, Lam, VK, Lewis, WE, Kemp, HN, Carter, B, Roth, JA, Swisher, SG, Lee, R, Zhou, T, Poteete, A, Kong, Y, Takehara, T, Paula, AG, Parra Cuentas, ER, Behrens, C, Wistuba, II, Zhang, J, Blumenschein, GR, Gay, CM, Byers, LA, Gibbons, DL, Tsao, A, Lee, JJ, Bivona, T, Camidge, DR, Gray, J, Lieghl, N, Levy, BP, Brahmer, JR, Garassino, MC, Gandara, D, Garon, EB, Rizvi, NA, Scagliotti, G, Wolf, J, Planchard, D, Besse, B, Herbst, RS, Wakelee, HA, Pennell, N, Shaw, AT, Jänne, PA, Carbone, DP, Hellmann, MD, Rudin, CM, Albacker, LA, Mann, H, Zhu, Z, Lai, Z, Stewart, RA, Peters, S, Johnson, M, Wong, KK, Huang, A, Winslow, MM, Rosen, MJ, Winters, IP, Papadimitrakopoulou, VA, Cascone, T, Jewsbury, P, Heymach, JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 635(8038):462-471, 2024. e-Pub 2024. PMID: 39385035.
- Araujo, HA, Pechuan-Jorge, X, Zhou, T, Do, MT, Hu, X, Rojas Alvarez, F, Salvatierra De Aranguren, M, Ibarguen, H, Lee, R, Raghulan, R, Shah, H, Ayala, MA, Chen, K, Tovbis Shifrin, N, Wu, S, Solis Soto, LM, Vailati Negrao, M, Gibbons, DL, Hong, DS, Roth, JA, Heymach, JV, Zhang, J, Jiang, J, Singh, M, Smith, JA, Quintana, E, Skoulidis, F. Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer. Cancer Discov 14(11):2183-2208, 2024. e-Pub 2024. PMID: 38975897.
- Zhou, N, Leung, CH, William Jr, WN, Weissferdt, A, Pataer, A, Godoy, M, Carter, B, Fossella, FV, Tsao, A, Blumenschein, GR, Le, X, Zhang, J, Skoulidis, F, Kurie, JM, Altan, M, Lu, C, Glisson, BS, Byers, LA, Elamin, YY, Mehran, RJ, Rice, DC, Walsh, GL, Hofstetter, WL, Roth, JA, Tran, HT, Wu, J, Solis Soto, LM, Kadara, HN, Swisher, SG, Vaporciyan, AA, Gibbons, DL, Lin, HY, Jack Lee, J, Heymach, JV, Vailati Negrao, M, Sepesi, B, Cascone, T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
- Pan, K, Owens, J, Elamin, YY, Lu, C, Routbort, MJ, Zhang, J, Fossella, FV, Vailati Negrao, M, Altan, M, Pozadzides, JV, Skoulidis, F, Tsao, A, Cascone, T, Heymach, JV, Ostrin, EJ, Le, X. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations. J Thorac Oncol 19(10):1438-1448, 2024. e-Pub 2024. PMID: 38866326.
- Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee JJ, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, Vaporciyan AA, Heymach JV, Zhang J, Le X. Real-world efficacy and safety of amivantamab for EGFR-mutant NSCLC. J Thorac Oncol 19(3):500-506, 2024. e-Pub 2024. PMID: 38012986.
- Zhang, B, Lewis, WE, Stewart, C, Morris, BB, Solis Soto, LM, Serrano, A, Xi, Y, Wang, Q, Lopez, ER, Concannon, K, Heeke, S, Tang, X, Raso, G, Cardnell, R, Vokes, N, Blumenschein, GR, Elamin, YY, Fosella, F, Tsao, A, Skoulidis, F, Hume, CB, Sasak, K, Lewis, J, Rinsurongkawong, W, Rinsurongkawong, V, Lee, JJ, Tran, HT, Zhang, J, Gibbons, DL, Vaporciyan, AA, Wang, J, Park, K, Heymach, JV, Byers, LA, Gay, CM, Le, X. Brief Report : Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets. JTO Clin Res Rep 5(2), 2024. e-Pub 2024. PMID: 38357092.
- Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors. Am J Gastroenterol 118(9):1609-1617, 2023. e-Pub 2023. PMID: 37307533.
- Wang K, Du R, Roy-Chowdhuri S, Li ZT, Hong L, Vokes N, Elamin YY, Hume CB, Skoulidis F, Gay CM, Blumenschein G, Fossella FV, Tsao A, Zhang J, Karachaliou N, O'Brate A, Gann CN, Lewis J, Rinsurongkawong W, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Altan M, Le X. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clin Res Rep 4(8):100533, 2023. e-Pub 2023. PMID: 37649681.
- Boiarsky D, Lydon CA, Chambers ES, Sholl LM, Nishino M, Skoulidis F, Heymach JV, Luo J, Awad MA, Janne PA, Van Allen EM, Barbie DA, Vokes NI. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma. Ann Oncol 34(7):589-604, 2023. e-Pub 2023. PMID: 37121400.
- Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee HS, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Heymach JV, Zhang J, Wu J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health 5(7):e404-e420, 2023. e-Pub 2023. PMID: 37268451.
- Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, Yeboa DN, McAleer MF, Chung C, Woodhouse KD, McGovern SL, Wang C, Kim BYS, Weinberg JS, Briere TM, Elamin YY, Le X, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. J Immunother Cancer 11(7), 2023. e-Pub 2023. PMID: 37402581.
- Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov 13(7):1556-1571, 2023. e-Pub 2023. PMID: 37068173.
- Qian Y, Galan-Cobo A, Guijarro I, Dang M, Molkentine D, Poteete A, Zhang F, Wang Q, Wang J, Parra E, Panda A, Fang J, Skoulidis F, Wistuba II, Verma S, Merghoub T, Wolchok JD, Wong KK, DeBerardinis RJ, Minna JD, Vokes NI, Meador CB, Gainor JF, Wang L, Reuben A, Heymach JV. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. Cancer Cell 41(7):1363-1380.e7, 2023. e-Pub 2023. PMID: 37327788.
- Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, Sacher AG, Takahashi T, Ramalingam SS, Dooms C, Kim DW, Addeo A, Desai J, Schuler M, Tomasini P, Hong DS, Lito P, Tran Q, Jones S, Anderson A, Hindoyan A, Snyder W, Skoulidis F, Li BT. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. J Clin Oncol 41(18):3311-3317, 2023. e-Pub 2023. PMID: 37098232.
- Formica V, Morelli C, Conca V, Calegari MA, Lucchetti J, Dell'Aquila E, Schirripa M, Messina M, Salvatore L, Lo Prinzi F, Dima G, Trovato G, Riondino S, Roselli M, Skoulidis F, Arkenau HT, Cremolini C. Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis. Cancers (Basel) 15(11), 2023. e-Pub 2023. PMID: 37297026.
- de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L, Investigators C. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet 401(10378):733-746, 2023. e-Pub 2023. PMID: 36764316.
- Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
- Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J, Vokes NI. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun 14(1):695, 2023. e-Pub 2023. PMID: 36755027.
- Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer 174:112-117, 2022. e-Pub 2022. PMID: 36371941.
- Ricciuti B, Alessi JV, Elkrief A, Wang X, Cortellini A, Li YY, Vaz VR, Gupta H, Pecci F, Barrichello A, Lamberti G, Nguyen T, Lindsay J, Sharma B, Felt K, Rodig SJ, Nishino M, Sholl LM, Barbie DA, Negrao MV, Zhang J, Cherniack AD, Heymach JV, Meyerson M, Ambrogio C, Jänne PA, Arbour KC, Pinato DJ, Skoulidis F, Schoenfeld AJ, Awad MM, Luo J. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann Oncol 33(10):1029-1040, 2022. e-Pub 2022. PMID: 35872166.
- Skoulidis F, Heymach JV, Cascone T. A STING operation to expose KRAS and STK11 co-mutated lung cancers. Cancer Cell 40(10):1073-1076, 2022. e-Pub 2022. PMID: 36220070.
- Thein KZ, Biter AB, Banks KC, Duda AW, Saam J, Roszik J, Janku F, Skoulidis F, Heymach JV, Kopetz S, Meric-Bernstam F, Hong DS. Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer. JCO Precis Oncol 6:e2100547, 2022. e-Pub 2022. PMID: 35862868.
- Bauml JM, Li BT, Velcheti V, Govindan R, Curioni-Fontecedro A, Dooms C, Takahashi T, Duda AW, Odegaard JI, Cruz-Guilloty F, Jin L, Zhang Y, Anderson A, Skoulidis F. Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib. Lung Cancer 166:270-278, 2022. e-Pub 2022. PMID: 34838325.
- Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, Zhang J, Tolstorukov MY, Li YY, Spurr LF, Cherniack AD, Recondo G, Lamberti G, Wang X, Venkatraman D, Alessi JV, Vaz VR, Rizvi H, Egger J, Plodkowski AJ, Khosrowjerdi S, Digumarthy S, Park H, Vaz N, Nishino M, Sholl LM, Barbie D, Altan M, Heymach JV, Skoulidis F, Gainor JF, Hellmann MD, Awad MM. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. J Thorac Oncol 17(3):399-410, 2022. e-Pub 2022. PMID: 34740862.
- Galan-Cobo A, Stellrecht CM, Yilmaz E, Yang C, Qian Y, Qu X, Akhter I, Ayres ML, Fan Y, Tong P, Diao L, Ding J, Giri U, Gudikote J, Nilsson M, Wierda WG, Wang J, Skoulidis F, Minna JD, Gandhi V, Heymach JV. Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. Mol Cancer Res 20(2):280-292, 2022. e-Pub 2022. PMID: 34654720.
- Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GR. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun 30:100514, 2022. e-Pub 2022. PMID: 35051703.
- Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, Lin HY, Udagawa H, Skoulidis F, Tran H, Varghese S, He J, Zhang F, Nilsson MB, Hu L, Poteete A, Rinsurongkawong W, Zhang X, Ren C, Liu X, Hong L, Zhang J, Diao L, Madison R, Schrock AB, Saam J, Raymond V, Fang B, Wang J, Ha MJ, Cross JB, Gray JE, Heymach JV. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 597(7878):732-737, 2021. e-Pub 2021. PMID: 34526717.
- Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer 9(8), 2021. e-Pub 2021. PMID: 34376553.
- Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, Italiano A, Schuler M, Borghaei H, Barlesi F, Kato T, Curioni-Fontecedro A, Sacher A, Spira A, Ramalingam SS, Takahashi T, Besse B, Anderson A, Ang A, Tran Q, Mather O, Henary H, Ngarmchamnanrith G, Friberg G, Velcheti V, Govindan R. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med 384(25):2371-2381, 2021. e-Pub 2021. PMID: 34096690.
- WSME T, Chen D, Verma V, Hobbs BP, Peulen HMU, JGJV A, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, Nguyen QN, Comeaux NI, Simon GR, Skoulidis F, Lin SH, He K, Patel R, Heymach J, Baas P, Welsh JW. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 9(5):467-475, 2021. e-Pub 2021. PMID: 33096027.
- Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
- Welsh JW, Heymach JV, Guo C, Menon H, Klein K, Cushman TR, Verma V, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Comeaux N, Patel RR, Chen D, Ozgen T, Nguyen QN, Chang JY, Altan M, Zhang J, Papadimitrakopoulou VA, Simon GR, Byers LA, Glisson B. Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. J Thorac Oncol 15(12):1919-1927, 2020. e-Pub 2020. PMID: 32916308.
- Cortez MA, Masrorpour F, Ivan C, Zhang J, Younes AI, Lu Y, Estecio MR, Barsoumian HB, Menon H, da Silva Caetano M, Ramapriyan R, Schoenhals JE, Wang X, Skoulidis F, Wasley MD, Calin G, Hwu P, Welsh JW. Author Correction: Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nat Commun 11(1):5144, 2020. e-Pub 2020. PMID: 33033261.
- Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, Hess K, de Groot P, Nguyen QN, Varghese R, Comeaux NI, Simon G, Skoulidis F, Chang JY, Papdimitrakopoulou V, Lin SH, Heymach JV. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer 8(2), 2020. e-Pub 2020. PMID: 33051340.
- Mitchell KG, Parra ER, Zhang J, Nelson DB, Corsini EM, Villalobos P, Moran CA, Skoulidis F, Wistuba II, Fujimoto J, Roth JA, Antonoff MB, Group MD. LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. Ann Thorac Surg 110(4):1131-1138, 2020. e-Pub 2020. PMID: 32442617.
- Cortez MA, Masrorpour F, Ivan C, Zhang J, Younes AI, Lu Y, Estecio MR, Barsoumian HB, Menon H, Caetano MDS, Ramapriyan R, Schoenhals JE, Wang X, Skoulidis F, Wasley MD, Calin G, Hwu P, Welsh JW. Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nat Commun 11(1):4840, 2020. e-Pub 2020. PMID: 32973129.
- Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
- Della Corte CM, Sen T, Gay CM, Ramkumar K, Diao L, Cardnell RJ, Rodriguez BL, Stewart CA, Papadimitrakopoulou VA, Gibson L, Fradette JJ, Wang Q, Fan Y, Peng DH, Negrao MV, Wistuba II, Fujimoto J, Solis Soto LM, Behrens C, Skoulidis F, Heymach JV, Wang J, Gibbons DL, Byers LA. STING pathway expression identifies non-small cell lung cancers with an immune-responsive phenotype. J Thorac Oncol 15(5):777-791, 2020. e-Pub 2020. PMID: 32068166.
- Gainor JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, Yeap BY, Naidoo J, Khosrowjerdi S, Mooradian M, Lydon C, Illei P, Zhang J, Peterson R, Ricciuti B, Nishino M, Zhang J, Roth JA, Grishman J, Anderson D, Little BP, Carter BW, Arbour K, Sauter JL, Mino-Kenudson M, Heymach JV, Digumarthy S, Shaw AT, Awad MM, Hellmann MD. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression =50. Ann Oncol 31(3):404-411, 2020. e-Pub 2020. PMID: 32067682.
- Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2020. PMID: 31778797.
- Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Menon H, Nguyen QN, Chang JY, Altan M, Papadimitrakopoulou VA, Simon GR, Raju U, Byers L, Glisson B. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol 15(2):266-273, 2020. e-Pub 2020. PMID: 31605794.
- Ruiz-Cordero R, Ma J, Khanna A, Lyons G, Rinsurongkawong W, Bassett R, Guo M, Routbort MJ, Zhang J, Skoulidis F Heymach J, Roarty EB, Tang Z, Medeiros LJ, Patel KP, Luthra R, Roy-Chowdhuri S. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer 20(1):83, 2020. e-Pub 2020. PMID: 32005111.
- Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, Parlati F, Wang J, Gandhi V, Skoulidis F, DeBerardinis RJ, Minna JD, Heymach JV. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma. Cancer Res 79(13):3251-3267, 2019. e-Pub 2019. PMID: 31040157.
- Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol 37(18):1558-1565, 2019. e-Pub 2019. PMID: 31067138.
- Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov 8(9):1156-1175, 2018. e-Pub 2018. PMID: 30012853.
- Chen L, Diao L, Yang Y, Yi X, Rodriguez L, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, Lorenzi PL, Gibbons DL, Peng D, Fradette J, Peng DH, Ungewiss C, Roybal JD, Tong P, Oba J, Skoulidis F, Peng W, Ungewiss C, Roybal JD, Tong P, Oba J, Skoulidis F, Peng W, Gay CM, Fan Y, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dimitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Quin X. CD38-mediated Immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade, CD38-mediated resistance to PD-1/PD-L1 blockade. Cancer Discov, 2018. e-Pub 2018.
- Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8(7):822-835, 2018. e-Pub 2018. PMID: 29773717.
- Singh A, Ruiz C, Bhalla K, Haley JA, Li QK, Acquaah-Mensah G, Montal E, Sudini KR, Skoulidis F, Wistuba II, Papadimitrakopoulou V, Heymach JV, Boros LG, Gabrielson E, Carretero J, Wong KK, Haley JD, Biswal S, Girnun GD. De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer. FASEB J:fj201800204, 2018. e-Pub 2018. PMID: 29906244.
- Tang KJ, Constanzo JD, Venkateswaran N, Melegari M, Ilcheva M, Morales JC, Skoulidis F, Heymach JV, Boothman DA, Scaglioni PP. Focal Adhesion Kinase regulates the DNA damage response and its inhibition radiosensitizes mutant KRAS lung cancer. Clin Cancer Res 22(23):5851-5863, 2016. e-Pub 2016. PMID: 27220963.
- Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17(12):1672-1682, 2016. e-Pub 2016. PMID: 27789196.
- Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE 2 Study : A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. J Clin Oncol, 2016. e-Pub 2016. PMID: 27480147.
- Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, Diao L, Wang J, Parra-Cuentas ER, Wistuba II, Soucheray M, Thai T, Asahina H, Kitajima S, Altabef A, Cavanaugh JD, Rhee K, Gao P, Zhang H, Fecci PE, Shimamura T, Hellmann MD, Heymach JV, Hodi FS, Freeman GJ, Barbie DA, Dranoff G, Hammerman PS, Wong KK. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res 76(5):999-1008, 2016. e-Pub 2016. PMID: 26833127.
- Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial to mesenchymal transition. Clin Cancer Res 22(3):609-20, 2016. e-Pub 2016. PMID: 26420858.
- Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discov 5(8):860-77, 2015. e-Pub 2015. PMID: 26069186.
- Chandra A, Grecco HE, Pisupati V, Perera D, Cassidy L, Skoulidis F, Ismail SA, Hedberg C, Hanzal-Bayer M, Venkitaraman AR, Wittinghofer A, Bastiaens PI. The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins. Nat Cell Biol 14(2):148-158, 2012. e-Pub 2012. PMID: 22179043.
- Hattori H, Skoulidis F, Russell P, Venkitaraman AR. Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor. Mol Cancer Ther 10(4):670-678, 2011. e-Pub 2011. PMID: 21289082.
- Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, Karreth FA, Lim M, Barber LM, Clatworthy SA, Davies SE, Olive KP, Tuveson DA, Venkitaraman AR. Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 18(5):499-509, 2010. e-Pub 2010. PMID: 21056012.
- Kiani-Alikhan S, Skoulidis F, Barroso A, Nuovo G, Ushiro-Lumb I, Breuer J, Lister A, Mattes F. Enterovirus infection of neuronal cells post-Rituximab. Br J Haematol 146(3):333-335, 2009. e-Pub 2009. PMID: 19466969.
- Formica V, Massara MC, Portarena I, Fiaschetti V, Grenga I, Del Vecchio Blanco G, Sileri P, Tosetto L, Skoulidis F, Pallone F, Roselli M. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients. Cancer Biomark 5(4):167-175, 2009. e-Pub 2009. PMID: 19729826.
- Skoulidis F, Morgan MS, MacLeod KM. Penicillium marneffei: a pathogen on our doorstep?. J R Soc Med 97(8):394-396, 2004. e-Pub 2004. PMID: 15286196.
Invited Articles
- Skoulidis F, Papadimitrakopoulou VA. Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-small Cell Lung Cancer. Clin Cancer Res 23(3):618-622, 2017. e-Pub 2017. PMID: 27821604.
- Skoulidis F, Papadimitrakopoulou VA. Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor. Clin Cancer Res, 2016. e-Pub 2016. PMID: 27609840.
- Skoulidis F, Cunningham D. Monoclonal antibodies cetuximab and bevacizumab in combination with irinotecan in colorectal cancer therapy: comments on regulatory approved indications. Advances in Colorectal Cancer, 2005. e-Pub 2005.
Review Articles
- Mascaux C, Sen T, Sanchez-Cespedes M, Ortiz-Cuaran S, Bosse Y, Dammeijer F, Cavic M, Barr MP, Arulananda S, Armisen R, Berger AH, Bianchi F, Carbone DP, Cerciello F, Lockwood WW, Mitsudomi T, Ohara S, Politi K, Qin S, Roisman LC, Samstein R, Skoulidis F, Tan AC, Thomas A, Zhang J, Wynes MW, John T, Tsao MS. Advances in Lung Cancer Basic and Translational Research in 2025 - Overview and Perspectives Focusing on NSCLC. J Thorac Oncol, 2025. e-Pub 2025. PMID: 40473107.
- Lim TKH, Skoulidis F, Kerr KM, Ahn MJ, Kapp JR, Soares FA, Yatabe Y. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing. Lung Cancer 184:107293, 2023. e-Pub 2023. PMID: 37683526.
- Remon J, Passiglia F, Ahn MJ, Barlesi F, Forde PM, Garon EB, Gettinger S, Goldberg SB, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper KA, Skoulidis F, Reck M, Adjei AA, Scagliotti GV. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. J Thorac Oncol 15(6):914-947, 2020. e-Pub 2020. PMID: 32179179.
- Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer 19(9):495-509, 2019. e-Pub 2019. PMID: 31406302.
- Skoulidis F, Alexander GJ, Davies SE. Ma huang associated acute liver failure requiring liver transplantation. Eur J Gastroenterol Hepatol 17(5):581-584, 2005. e-Pub 2005. PMID: 15827451.
Other Articles
- Skoulidis, F, Araujo, HA, Do, MT, Qian, Y, Sun, X, Cobo, AG, Le, JT, Montesion, M, Palmer, R, Jahchan, NS, Juan, J, Min, C, Yu, Y, Pan, X, Arbour, KC, Vokes, N, Schmidt, S, Molkentine, D, Owen, D, Memmott, R, Patil, P, Marmarelis, ME, Awad, MM, Murray, J, Hellyer, JA, Gainor, J, Dimou, A, Bestvina, CM, Shu, CA, Riess, JW, Blakely, CM, Pecot, CV, Mezquita, L, Tabbò, F, Scheffler, M, Digumarthy, S, Mooradian, MJ, Sacher, A, Lau, SC, Saltos, A, Rotow, JK, Johnson, RP, Liu, C, Stewart, TF, Goldberg, SB, Killam, J, Walther, Z, Schalper, K, Davies, KD, Woodcock, MG, Anagnostou, V, Marrone, KA, Forde, PM, Ricciuti, B, Venkatraman, D, Van Allen, EM, Cummings, AL, Goldman, JW, Shaish, H, Kier, M, Katz, S, Aggarwal, C, Ni, Y, Azok, J, Segal, J, Ritterhouse, LL, Neal, JW, Lacroix, L, Elamin, YY, Vailati Negrao, M, Le, X, Lam, VK, Lewis, WE, Kemp, HN, Carter, B, Roth, JA, Swisher, S, Lee, R, Zhou, T, Poteete, A, Kong, Y, Takehara, T, Paula, AG, Parra Cuentas, ER, Behrens, MC, Wistuba, II, Zhang, J, Blumenschein, GR, Gay, CM, Byers, LA, Gibbons, DL, Tsao, A, Lee, JJ, Bivona, T, Camidge, DR, Gray, JE, Leighl, NB, Levy, BP, Brahmer, JR, Garassino, MC, Gandara, D, Garon, EB, Rizvi, NA, Scagliotti, G, Wolf, J, Planchard, D, Besse, B, Herbst, RS, Wakelee, HA, Pennell, N, Shaw, AT, Jänne, PA, Carbone, DP, Hellmann, MD, Rudin, CM, Albacker, LA, Mann, H, Zhu, Z, Lai, Z, Stewart, RA, Peters, S, Johnson, M, Wong, KK, Huang, A, Winslow, MM, Rosen, MJ, Winters, IP, Papadimitrakopoulou, VA, Cascone, T, Jewsbury, P, Heymach, JV Correction to "CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors" (Nature, (2024), 635, 8038, (462-471), 10.1038/s41586-024-07943-7). Nature 639(8054):E19, 2025. PMID: 40016449.
- Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, Sacher AG, Takahashi T, Ramalingam SS, Dooms C, Kim DW, Addeo A, Desai J, Schuler M, Tomasini P, Hong DS, Lito P, Tran Q, Jones S, Anderson A, Hindoyan A, Snyder W, Skoulidis F, Li BT Long-term benefit of sotorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: plain language summary. Future Oncol 20(3):113-120, 2024. PMID: 38010044.
Editorials
- Skoulidis F. Transcription Strikes Back: Clinical Utility of Lung Adenocarcinoma Subtypes. Clin Cancer Res 27(4):913-915, 2021. PMID: 33328344.
Book Chapters
- Skoulidis F, Eisen T. Targeted therapies for metastatic conventional – type renal cell carcinoma. In: Renal Cell Carcinoma (Oxford American Oncology Library). OUP, 2014.
- Skoulidis F, Chua YJ, Cunningham D. Squamous cancer of the esophagus. In: Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach. Blackwell Publishing Ltd, 114-145, 2009.
Patient Reviews
CV information above last modified March 24, 2026